GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Effective Interest Rate on Debt %

Artelo Biosciences (Artelo Biosciences) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Artelo Biosciences's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. Artelo Biosciences's average total debt for the quarter that ended in Mar. 2024 was $0.08 Mil. Therefore, Artelo Biosciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.


Artelo Biosciences Effective Interest Rate on Debt % Historical Data

The historical data trend for Artelo Biosciences's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Effective Interest Rate on Debt % Chart

Artelo Biosciences Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 6.33 -

Artelo Biosciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Artelo Biosciences's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Artelo Biosciences's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Effective Interest Rate on Debt % falls into.



Artelo Biosciences Effective Interest Rate on Debt % Calculation

Artelo Biosciences's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (0.063+0.023)/ 2 )
=-1  *  0/0.043
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.023 + 0.04
=0.063

Artelo Biosciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  0/( (0.023+0.127)/ 2 )
=-1  *  0/0.075
=0.00 %

where

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.096 + 0.031
=0.127

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Artelo Biosciences  (NAS:ARTLW) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Artelo Biosciences Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences (Artelo Biosciences) Business Description

Industry
Traded in Other Exchanges
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.